Drug · CHEMBL191
LOSARTAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LOSARTAN. Drugs and targets, record CHEMBL191. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL191
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Allisartan, Angizaar, Dup-89, E-3174, EXP3174, Exp-3174, HGP-1405, HGP1405, Losartan carboxylic acid, Losartic, Lozap, NSC-758699
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | Type-1 angiotensin II receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/185 |
Source ChEMBL
Diseases95
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 95Source Open Targets
See all 95 diseasesTrials310
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 67 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00090259 | Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948) | Phase 3 | 3,834 | 2010-08-02 | losartan | Its name | ClinicalTrials.gov |
| NCT00555217 | VA NEPHRON-D: Diabetes iN Nephropathy Study | Phase 3 | 1,448 | 2015-05-29 | losartan | Its name | ClinicalTrials.gov |
| NCT00429364 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome | Phase 3 | 608 | 2015-04-01 | losartan | Its name | ClinicalTrials.gov |
| NCT00922480 | Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients | Phase 3 | 506 | 2018-02-13 | losartan | Its name | ClinicalTrials.gov |
| NCT00219141 | Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension | Phase 3 | 460 | 2011-05-10 | losartan | Its name | ClinicalTrials.gov |
| NCT00888355 | MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension | Phase 3 | 428 | 2009-06-24 | losartan | Its name | ClinicalTrials.gov |
| NCT02235909 | An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension | Phase 3 | 377 | 2025-02-25 | losartan | Its name | ClinicalTrials.gov |
| NCT01277822 | Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399) | Phase 4 | 334 | 2014-04-24 | losartan | Its name | ClinicalTrials.gov |
| NCT01371747 | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | Phase 2 | 324 | 2015-12-17 | losartan | Its name | ClinicalTrials.gov |
| NCT00568178 | An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) | Phase 3 | 306 | 2009-10-30 | losartan | Its name | ClinicalTrials.gov |
1 to 10 of 310
See all 310 trialsComparisons in its trials90
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Were Hospitalized for Heart Failure | 503 of 1,913 | 450 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Died (Any Cause) | 665 of 1,913 | 635 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | 889 of 1,913 | 828 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | 1,085 of 1,913 | 1,037 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced Cardiovascular Hospitalization | 826 of 1,913 | 762 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: serious adverse events | 691 of 1,913 | 710 of 1,921 | 3,834 | NCT00090259 | Trial comparisons |
Combination of ARB and ACEI vs Monotherapy ARB: A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death | 132 of 724 | 152 of 724 | 1,448 | NCT00555217 | Trial comparisons |
Combination of ARB and ACEI vs Monotherapy ARB: A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD. | 77 of 724 | 101 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| Combination of ARB and ACEI vs Monotherapy ARB: serious adverse events | 416 of 724 | 380 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| Atenolol vs Losartan: Number of Death. | 0 of 303 | 1 of 305 | 608 | NCT00429364 | Trial comparisons |
1 to 10 of 90
See all 90 comparisons in its trialsPapers from its trials221
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials8
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Antisaccade Task | 1 | 1 | ConductCognition |
| Approach-Avoidance Task | 1 | 0 | ConductCognition |
| Dot-Probe Task | 1 | 0 | ConductCognition |
| Mnemonic Similarity Task | 1 | 0 | ConductCognition |
| Oddball Target Detection | 1 | 1 | ConductCognition |
| Paced Visual Serial Addition Test | 1 | 1 | ConductCognition |
| Symbol Coding | 1 | 1 | ConductCognition |
| Task Switching Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL191
GET https://conductscience.org/api/drugs/v1/CHEMBL191/diseases?page=2